跳至主要内容
临床试验/EUCTR2010-023122-21-GB
EUCTR2010-023122-21-GB进行中(未招募)1 期

Pro-Bono 2- A prospective study of loss of bone mineral density in patients with HIV over time: implications for clinical practice and therapeutic options: Vitamin D sub study. - Pro-Bono-2 Vitamin D SubStudy

King's College London0 个研究点目标入组 0 人开始时间: 2011年10月10日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • Aged between 18 years and 45 years , Males and Females
  • Documented Positive HIV-1 antibody test and either stable on HAART as defined by undetectable viral load and on the same regimen for =6 months or treatment naive (HIV+ cohort only) (n=32)
  • Presumed HIV negative –(HIV negative cohort only) (n=16)
  • Ability to give informed consent
  • Females willing to use barrier method contraception (condoms) for the duration of the trial.
  • Documented Vitamin D deficiency (less than 50 nmol/L within 6 months of screening)
  • Not currently taking Vitamin D supplements, or has taken any Vitamin D supplements within 4 weeks of screening
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 48
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Pregnancy or breast feeding
  • Patient unlikely to comply with protocol
  • 1Received vitamin D supplementation within the previous 4 weeks.
  • Documented history of renal impairment
  • Any chronic inflammatory condition
  • Documented Hepatitis B or C
  • Documented soya or peanut allergy or hypersensitivity to any of the constituents of Dekristol®
  • Hypercalcaemia or hypercalciuria
  • Pseudohypoparathyroidism

研究者

相似试验

This study aims to look at the effect of a high dose... | 临床试验